novo nordisk semaglutide patent Ozempic's problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Off-patent semaglutide in 2026: the

PubMed Central, Doherty, Taylor A., and Andrew A

This is an important study because its the first time a weight loss drug has been shown to reduce the risk of heart disease, including the risk of death, says Howard Weintraub, MD, clinical director of the Center for the Prevention of Cardiovascular Disease, part of NYU Langone Heart

After you return to eating normally, you gain back any losses

Weight loss may be slow initially, and you usually see the benefits a few weeks after being on these medications when your dose is increased

By the time celebrity adoption pushed the brand name into the cultural bloodstream, the underlying medicine had already done the harder work